"RESPINOR DXT simplifies diaphragm function assessment in critical care with user-friendly DXT sensors, for actionable diagnostics, and streamlined placement using DXT tape. Our aim is to improve patient outcomes, reduce reintubation rates, and lower healthcare costs, aligning with the European Society of Intensive Care Medicine's endorsement of diaphragm assessment as a fundamental skill for intensivists."
Our cutting-edge technology provides a precise and non-invasive measure of diaphragm function. Equipped with DXT sensors optimized for patient comfort, it offers continuous monitoring for over 24 hours in real-time. Easy to use and requiring no ultrasound expertise, our system provides actionable diagnostic output for identifying diaphragm dysfunction.
The inclusion of DXT tape with integrated ultrasound gel streamlines sensor placement through computer assistance. Our primary goal is to optimize extubation timing, reduce reintubation rates, and improve patient outcomes. By achieving these objectives, we contribute to optimizing patient care,lowering healthcare costs, ensuring a more efficient and effective approach to critical care.
"I was impressed by your device and your signal. I believe there is a lot to do with your system, to monitor the diaphragm in ICU patients, but also way beyond this application."
- ICU Spesialist France
Mechanical ventilation (MV) is one of the most common therapies in the intensive care unit (ICU), and is a treatment patients only receive in the most life-critical situations. Every extra day a patient is on MV, the risk of permanent impairment to the breathing ability increases along with treatment costs. Therefore, it is highly important to bring patients off MV and back to spontaneous breathing as quickly as possible. When the diaphragm is strong enough for patients to breathe by themselves.
There is currently a lack of accurate and cost-effective solutions to support this process – and the introduction of new technologies is highly warranted. Respiratory problems and respiratory failure after extubation can often be directly linked with diaphragm dysfunction. However, monitoring of the diaphragm is not routinely performed, meaning that diaphragm dysfunction is often under-recognized. The introduction of RESPINOR DXT represents a paradigm shift.
Patients are put on MV because they are unable to sustain breathing on their own. MV is a critical, life-sustaining treatment; however, it is also associated with several risks including diaphragm muscle atrophy (shrinkage due to underuse), and muscle fiber damage caused by unloading of the diaphragm as the ventilator assumes control of respiration. Diaphragm impairment has been documented to affect patients as soon as oneday after commencing MV. The diaphragm contributes to 70-75% of the air we breathe in. To avoid extensive damage to the diaphragm, the specialist must balance the need for MV to maintain adequate gas exchange with getting patients off the ventilator as early as possible.
Today’s Standard of care for weaning from a ventilator is to perform a spontaneous breathing trial, (SBT) where the support from the ventilator is decreased and the specialists assess the stability of the cardiovascular systems, adequate oxygenation, and pulmonary function. However, the standard of care today does not include monitoring of the diaphragm, hence does not uncover diaphragm dysfunction which may lead to reintubation.
The risks associated with reintubation are severe and include increased cardiac and respiratory complications, prolonged length of ICU and hospital stay, prolonged MV support, increased mortality, and higher costs.